US Stock MarketDetailed Quotes

CCJ Cameco

Watchlist
  • 44.040
  • +0.560+1.29%
Close Feb 28 16:00 ET
  • 43.770
  • -0.270-0.61%
Post 20:01 ET
19.17BMarket Cap163.11P/E (TTM)

Cameco Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Cameco Q4 2024 Earnings Date

Currency：USDFeb 20, 2025

Estimate
(YoY)		 Actual
(YoY)		 Vs Estimate
(% Chg)
Revenue
759.63M
824.28M
+64.65M
Beat Est.
+19.31%
+29.51%
+8.51%
EPS
0.26
0.22
-0.05
Miss Est.
+92.42%
+59.05%
-17.34%
Analyst Rating
Strong Buy

Mar 1, 2025

Cameco Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 2 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: CAD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 857.311M--
--2025/Q1-- / 907.984M--
Feb 20, 20252024/Q41.183B / 1.090B--
Nov 7, 20242024/Q3720.596M / 751.814M--
Jul 31, 20242024/Q2598.458M / 750.461M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q2-- / 857.311M--
--2025/Q1-- / 907.984M--
Feb 20, 20252024/Q41.183B / 1.090B--
Nov 7, 20242024/Q3720.596M / 751.814M--
Jul 31, 20242024/Q2598.458M / 750.461M--

Unlock Free Earnings Estimates

Cameco Earnings Reports

  • Cameco | 6-K: Report of foreign private issuer (related to financial reporting)

    Feb 20 07:31 ET

  • Cameco | 6-K: Report of foreign private issuer (related to financial reporting)

    Jan 23 12:02 ET

  • Cameco | 6-K: Report of foreign private issuer (related to financial reporting)

    Nov 13, 2024 14:52 ET

  • Cameco | 6-K: Report of foreign private issuer (related to financial reporting)

    Nov 7, 2024 06:53 ET

    • Read more

    Trending Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    Cars.com
    CARS
    +9.73%
    Lantheus
    LNTH
    +2.55%
    Halozyme Therapeutics
    HALO
    +2.51%
    DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
    DMZPY
    +2.27%
    Collegium Pharmaceutical
    COLL
    +2.22%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Mar 1, 2025

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data

    Investment Theme Nuclear Power
    Nuclear Power
    Intraday+1.28%